Five-Year In-Hospital Outcomes After Percutaneous LAA Closure Reported From Nationwide German Study
June 10, 2019—Findings from a large study evaluating 5-year in-hospital trends and safety outcomes of left atrial appendage (LAA) closure in a German nationwide inpatient sample were published by Lukas Hobohm, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
The study found that the use of percutaneous LAA closure increased 3.6-fold in Germany from 2011 to 2015, with a nonsignificant uptrend of in-hospital mortality rates in this real-world setting. Important predictors of in-hospital death were acute renal failure, pericardial effusion, and ischemic stroke during hospitalization.
As summarized in JACC: Cardiovascular Interventions, the investigators analyzed data on patient characteristics and in-hospital safety outcomes for all percutaneous LAA closures performed in Germany between 2011 and 2015. The study was composed of 15,895 inpatients.
The annual number of LAA occlusions increased from 1,347 in 2011 to 4,932 in 2015 (β = 1; 95% confidence interval [CI], 0.95–1.01; P < .001), with a nonsignificant uptrend of in-hospital mortality from 0.5% in 2011 to 0.9% in 2015 (β = 0.01; 95% CI, -0.09–0.32; P = .271).
Patient characteristics shifted toward older age and higher prevalence of comorbidities, including heart failure, chronic obstructive pulmonary disease, and chronic renal insufficiency over time. Important independent predictors of in-hospital mortality were:
- Cancer (odds ratio [OR], 2.49; 95% CI, 1–6.12; P = .05)
- Heart failure (OR, 2.42; 95% CI, 1.72–3.41; P < .001)
- Stroke (OR, 5.39; 95% CI, 2.76–10.53; P < .001)
- Acute renal failure (OR, 13.28; 95% CI, 9.08–19.42; P < .001)
- Pericardial effusion (OR, 5.65; 95% CI, 3.76–8.48; P < .001)
- Shock (OR, 45.11; 95% CI, 31.01–65.58; P < .001)
advertisement
Featured Video
Conquer the Calcium.
Deliver the Stent.
Sponsored by Cardiovascular Systems Inc.
Related Articles
Top 5 Articles From April 2019
TAVI: Which Valve for Which Patient?
A review of the technical challenges and optimal valve choices in different clinical and anatomic scenarios.
By Noman Ali, PhD; and Daniel J. Blackman, MD
Permanent Pacemaker Implantation After TAVR
Reviewing the current landscape of permanent pacemaker implantation post-TAVR and a look at the road ahead.
By Rahul Sharma, MD; and Rahul P. Sharma, MD
Bioprosthetic Valve Fracture During ViV TAVR
A step-by-step practical guide for performing BVF to facilitate ViV TAVR.
By Ahmed Almomani, MD; and Adnan K. Chhatriwalla, MD
Roundtable Discussion: TAVR in Low-Risk Patients
Experts discuss the significance of recent data and the potential impact on their practice.
With Kentaro Hayashida, MD, PhD, FESC, FACC, FJCS; Robert Ostfeld, MD, MSc, FACC; Bernard Prendergast, BMedSci, BM BS, MRCP, DM, FRCP, FESC; Michael J. Reardon, MD; and Steven J. Yakubov, MD, FACC, FSCAI
Simultaneous Measurement of Differential Pressures With a Dual Lumen Catheter
Using a dual lumen catheter to accurately measure pressures between two sites across a valve or stenosis.
By Christian Bradaric, MD
Top 5 from EVToday's Current Issue
What’s New in Y-90?
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR
Transradial Access for Hepatic Oncologic Interventions
Considerations for choosing the right access equipment.
By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC
Is It Time to End the Therapeutic Nihilism Toward Treating VTE in Cancer Patients?
Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.
With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC
Contemporary Management of Pancreatic Cancer
An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.
By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD
Top Tips in Interventional Oncology
Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.
